Table 1 Main effects of the models predicting functional outcome and long-term durability of treatment

Treatment

 Endovascular

Ref

Ref

Ref

Ref

 Neurosurgical

1.5 (1.3–1.7)

1.5 (1.3–1.7)

0.3 (0.2–0.4)

0.3 (0.2–0.4)

 Time-to-aneurysm-treatment (days)

1.05 (1.03–1.08)

1.02 (1.00–1.04)

0.96 (0.93–1.00)

Not included

Age (per decade)

 Linear

1.2 (1.18–1.35)

1.20 (1.12–1.28)

0.88 (0.78–0.99)

NA

  ≤ 52

NA

0.7 (0.6–0.9)

  > 52

NA

1.2 (0.9–1.5)

WFNS grade

 I

Ref

Ref

Ref

Not included

 II

2.1 (1.8–2.5)

1.9 (1.6–2.3)

1.1 (0.8–1.5)

 III

3.5 (2.6–4.8)

2.5 (1.8–3.5)

0.6 (0.3–1.3)

 IV

7.6 (4.9–11.5)

6.6 (4.3–10.1)

1.3 (0.6–2.9)

 V

10.6 (4.8–23.7)

9.4 (4.1–21.5)

0.8 (0.1–5.6)

CT Fisher grade

 1

Ref

Ref

Ref

Not included

 2

1.0 (0.7–1.5)

1.2 (0.8–1.8)

1.1 (0.5–2.2)

 3

1.6 (1.1–2.2)

1.6 (1.1–2.3)

1.2 (0.6–2.4)

 4

2.6 (1.8–3.6)

1.9 (1.3–2.7)

1.2 (0.6–2.3)

Aneurysm lumen size (mm)

1.05 (1.03–1.08)

1.05 (1.02–1.07)

1.06 (1.02–1.10)

1.06 (1.01–1.10)

Aneurysm neck size

  ≤ 4 mm

Ref

Not included

Ref

Not included

  > 4 mm

1.2 (1.0–1.4)

0.8 (0.6–1.1)

Aneurysm location

 ACA

Ref

Ref

Ref

Ref

 ACOM

1.0 (0.8–1.2)

0.9 (0.8–1.2)

1.6 (1.1–2.4)

1.6 (1.1–2.4)

 ICA

1.2 (0.9–1.5)

1.3 (1.0–1.6)

1.5 (1.0–2.3)

1.4 (0.9–2.1)

 MCA

1.0 (0.8–1.3)

0.9 (0.7–1.2)

1.3 (0.8–2.1)

1.2 (0.8–2.0)

 PCOM

1.1 (0.8–1.4)

1.0 (0.8–1.4)

1.2 (0.7–2.1)

1.1 (0.6–1.9)

 Posterior^c

1.1 (0.7–1.8)

1.0 (0.6–1.7)

1.3 (0.5–3.3)

1.5 (0.6–3.7)

Vasospasm at presentation

 Absent

Ref

Ref

Ref

Not included

 Present

1.6 (1.4–2.0)

1.2 (1.0–1.5)

0.9 (0.7–1.3)